Nearly three million Canadian adults are currently using GLP-1 medications such as Ozempic or Wegovy.. Recent research suggests these drugs are linked to a significantly higher risk of alopecia compared to other metabolic treatments.
A 68% higher risk compared to DPP-4 inhibitors
New data indicates that nearly three million Canadian adults are currently utilizing GLP-1 receptor agonists, primarily for weight loss or diabetes management . The study highlights a significant dermatological risk, finding that GLP-1 usage is associated with a 37% higher risk of alopecia when compared to SGLT-2 inhibitors. Even more striking is the 68% higher risk observed in comparison to those using DPP-4 inhibitors.
A recent survey released on Tuesday confirmed that while diabetes management is a key driver, weight loss is the number one reason people are currently taking or considering these medications. As the report notes, this massive increase in usage brings a new set of clinical considerations for both doctors and patients, particularly regarding the potential for non-scarring alopecia.
The three-month window for hair shedding
Dr.. Elena Netchiporouk, Quebec's regional director with the Canadian Dermatology Association, suggests that the hair loss is likely a byproduct of metabolic shifts rather than direct follicle damage. She explains that when the body experiences rapid weight loss, it enters a state of physiological stress. in these moments, the body prioritizes essential survival functions, meaning that hair and nail growth are deprioritized.
According to Netchiporouk, this typically manifests as a shedding period that begins approximately three months after a patient starts the medication. This shedding can last for about six months, but it is generally temporary. Once weight loss stabilizes, the hair typically grows back , as the condition is not considered a "dangerous" form of hair loss associated with the drugs themselves.
The FDA's investigation into semaglutide and tirzepatide
The U.S. Food and Drug Administration (FDA) is currently evaluating potential safety signals regarding hair loss following the use of GLP-1 receptor agonists. This investigation specifically targets semaglutide and tirzepatide, the active ingredients in popular drugs like Ozempic, Wegovy, and Mounjaro. The regulatory concern is bolstered by a global study of over one million participants, which found significantly increased hair loss rates among users of these drugs.
While hair loss may not cause direct physical harm, the report emphasizes that it can have profound psychosocial consequences. Issues such as diminished self-esteem and reduced quality of life can impact a patient's mental health and their willingness to adhere to their prescribed treatment regimen.
Why weight loss alone might not explain the alopecia
While rapid weight loss is a major factor, the source highlights several unanswered questions regarding the exact cause of the hair loss. A global study of more than one million participants suggested that the risk of alopecia may not be fully explained by rapid or extreme weight loss alone, hinting at more complex biological interactions that are not yet fully understood.
Additionally, there are concerns regarding nutritional deficiencies. The report notes that side effects like nausea and vomiting can lead to decreased food intake, which may further contribute to hair thinning. To mitigate these risks, Dr. Netchiporouk suggests that patients might consider a slower pace of weight loss—aiming for roughly one kilogram per week—or even using half of a minimal dose to allow the body to adjust more gradually.
Comments 0